Cancer Immunotherapy

PreclinicalBiologic

MMassachusetts General Hospital

Cancer Immunotherapy is one of 4 biologic programs targeting Chemoradiation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChemoradiationCompleted

ChemoradiationPreclinical

Completed

Competition

Competitive Landscape

4 competitors in Chemoradiation

#DrugCompanyPhaseTrials

Tuoyi

SSun Yat-sen University

Phase 2

1 2

S1,

CChinese Academy of Medical Sciences

Phase 2

1 3

Iparomlimab

TTianjin Medical University Cancer Institute and Hospital

Phase 2

1 4

Cancer Immunotherapy

MMassachusetts General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chemoradiation1 trial

A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy

Completed·MMassachusetts General Hospital·N/A·NCT02431572·11 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cancer Immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cancer Immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cancer Immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMassachusetts General Hospital

Cancer Immunotherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chemoradiation1 trial

References

Drug Info

Quick Facts

Related News